Comparison of M-2 Protocol with COP in Patients with Nodular Lymphoma

Publisher Website
Google Scholar
Abstract
58 consecutively referred, previously untreated patients with nodular lymphomas (stages III and IV) were treated with two different combination chemotherapy regimens – (cyclophosphamide, vincristine and prednisone (COP), and BNCU, cyclophosphamide, vincristine, melphalan and prednisone (M-2) – to compare remission induction and duration as well as survival. The two groups were comparable for age, stage IV and histology. The complete response for each combination was > 80%. Median duration of remission for the COP-treated patients is 18 months. Remission duration and survival are superior for M-2-treated patients. The difference in remission duration and survival advantage is statistically significant for the M-2 protocol compared with COP at 5 years (p < 0.01).